Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.7 |
mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |